Kala Pharmaceuticals (NASDAQ:KALA) posted its earnings results on Thursday. The company reported ($0.68) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.01), Fidelity Earnings reports. The firm had revenue of $1.45 million during the quarter, compared to the consensus estimate of $3.56 million.
KALA stock traded up $0.40 during midday trading on Friday, reaching $4.11. The company had a trading volume of 374,000 shares, compared to its average volume of 249,192. Kala Pharmaceuticals has a 1-year low of $3.24 and a 1-year high of $9.25. The company has a debt-to-equity ratio of 1.16, a current ratio of 7.50 and a quick ratio of 7.04. The stock has a 50 day moving average price of $3.84 and a 200-day moving average price of $5.11. The company has a market capitalization of $126.17 million, a price-to-earnings ratio of -1.66 and a beta of 2.13.
A number of equities research analysts have recently weighed in on the company. Zacks Investment Research raised Kala Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a report on Wednesday. Oppenheimer set a $9.00 price target on Kala Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 7th. Wedbush reaffirmed an “outperform” rating and issued a $51.00 price target on shares of Kala Pharmaceuticals in a research note on Wednesday, August 7th. ValuEngine raised Kala Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, JPMorgan Chase & Co. dropped their price target on Kala Pharmaceuticals from $22.00 to $14.00 and set an “overweight” rating for the company in a research note on Friday. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $17.54.
Kala Pharmaceuticals Company Profile
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
Read More: Why is the ROA ratio important?
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.